TCTMD (@TCTMD) header
TCTMD (@TCTMD) profile picture

Your source for breaking news, topical videos, and slides covering cardiovascular disease and interventions. Register at https://teapawt.org/t.co/9j3KOiiahQ

New York, NY
Joined May 2009
Photo by TCTMD (@TCTMD)Photo by TCTMD (@TCTMD)Photo by TCTMD (@TCTMD)Photo by TCTMD (@TCTMD)Photo by TCTMD (@TCTMD)Photo by TCTMD (@TCTMD)Photo by TCTMD (@TCTMD)Photo by TCTMD (@TCTMD)Photo by TCTMD (@TCTMD)Photo by TCTMD (@TCTMD)
US Veterans Face Unique Barriers to CV Health: AHA Statement. bit.ly/491FZC2
1
379
Many Strategies on the Table for Treatment of Calcified Coronary Lesions: TCT Session bit.ly/4zkpnA9
1
8
825
For patients with atrioventricular block, left bundle branch pacing produced better outcomes than right ventricular pacing in the randomized OptimPacing trial. bit.ly/4iL81q7
2
471
Can older adults without known CVD safely stop statins used for primary prevention? STREAM suggests discontinuation may be reasonable in select patients—but it’s not without risk. bit.ly/3Wx0AeE
1
1
3
710
SUPERIOR: Sacubitril/Valsartan May Lessen AF Recurrence After Ablation bit.ly/4kUMduA
1
2
857
In a post-hoc OCEANIC-STROKE analysis, asundexian was associated with better outcomes after noncardioembolic stroke or high-risk TIA regardless of baseline vascular risk according to Framingham Risk Score. bit.ly/3X6Yx0Z
4
840
Tight blood pressure control after an ischemic stroke or TIA lowers the risk of major adverse cardiovascular events over the next 4 years, the OPTIMAL-STROKE trial suggests. bit.ly/4zdiFff
4
750
Guiding DAPT De-escalation With Platelet Function Testing Doesn’t Improve Outcomes: EPIC17-VERONICA bit.ly/4kRsHiB
2
3
761
Can targeting inflammation still reduce cardiovascular events? ZEUS found no benefit with ziltivekimab, but experts say the inflammatory hypothesis may not be finished. bit.ly/4sXU2lt
613
Unhoused PAD Patients Require Nuanced Care, Data Suggest bit.ly/3UM0Eqp
547
Lp(a)HORIZON did not show the hoped-for cardiovascular benefits of reducing lipoprotein(a). Still, experts caution that one neutral trial does not end the pursuit of effective Lp(a)-lowering therapies. bit.ly/4iQa0t9
2
669
SCOUT-HCM: Mavacamten Maintains Benefits Through 56 Weeks bit.ly/4zK4W0w
402
This year's TCT Shark Tank winner, Loïc Van Horne, shares details about how Narwhal Medical created a blood pump designed for delivery through the radial artery. Hear more about the technology and vision behind its development in this TCTMD interview: bit.ly/4jeBglt
601
Widespread CPR Training Effort Didn’t Nudge OHCA Outcomes: RACE-CARS bit.ly/4zJuv1K
1
2
6
999
TCT 2026: New data and key takeaways for Paradise uRDN. Visit: bit.ly/48vfGE3 Explore real-world experience, four-year durability, sedation, hospital economics, and patient-centric analysis. Sponsored by @RecorMedical #Sponsored
1
410
Did you guess correctly? This week's episode features Nicolas Van Mieghem! Listen to the full episode for more on his guiding mantra in life, his effort to maintain a balance between ambition and family, and more: bit.ly/3WBuY7G @drnvanmieghem @TCTMD_Yael
1
1
483
Good Outcomes Maintained at 2 Years With Sapien M3 TMVR: ENCIRCLE bit.ly/3WuGUbn
1
2
689
The conversations from #TCT2026 keep coming. Mamas Mamas speaks with Rebecca Hahn about Australian data on severe tricuspid regurgitation and what it means for treatment decisions. Catch the full conversation behind the data, and stay tuned as our coverage continues: bit.ly/4AtpR8g
1
617
How much autonomy should AI be given? Tony Das and Aasif Qasim discuss the possibilities and areas of concern that were highlighted during a #TCT2026 session.
1
1
548
During Elective PCI, High- and Low-Dose Heparin Provide Similar Outcomes bit.ly/4iLNCB0
8
1,118